SkinBioTherapeutics PLC (SBTX) — Financial Flexibility Index
SkinBioTherapeutics PLC (SBTX) has a Financial Flexibility Index of -0.18x as of June 2025. Free cash flow of GBX-491.17K (operating CF GBX-494.84K minus capex GBX3.66K) represents 0% of total liabilities (GBX2.71 Million). Also explore SBTX net assets growth trend to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
SkinBioTherapeutics PLC Financial Flexibility Index (2016–2025)
Historical Financial Flexibility Index trend for SkinBioTherapeutics PLC across 10 annual periods. Check SBTX PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for SkinBioTherapeutics PLC (2016–2025)
Year-by-year free cash flow to debt coverage for SkinBioTherapeutics PLC. For the full company profile including market capitalisation, see SBTX company net worth.
| Year | Flexibility Index | Free Cash Flow (GBX) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.48x | GBX-1.29 Million | GBX-1.30 Million | GBX2.71 Million | ▲ +57.6% |
| 2024 | -1.13x | GBX-2.53 Million | GBX-2.73 Million | GBX2.25 Million | ▲ +72.8% |
| 2023 | -4.14x | GBX-2.48 Million | GBX-2.65 Million | GBX599.34K | ▲ +2.1% |
| 2022 | -4.23x | GBX-2.58 Million | GBX-2.67 Million | GBX609.61K | ▼ -52.2% |
| 2021 | -2.78x | GBX-1.44 Million | GBX-1.56 Million | GBX519.67K | ▼ -3.4% |
| 2020 | -2.69x | GBX-818.47K | GBX-892.14K | GBX304.83K | ▲ +77.0% |
| 2019 | -11.69x | GBX-1.42 Million | GBX-1.43 Million | GBX121.33K | ▼ -310.9% |
| 2018 | -2.85x | GBX-595.49K | GBX-667.75K | GBX209.29K | ▲ +36.4% |
| 2017 | -4.47x | GBX-530.50K | GBX-609.70K | GBX118.66K | ▼ -211.4% |
| 2016 | 4.01x | GBX135.05K | GBX-1.17K | GBX33.64K | — |